Investments
4Portfolio Exits
2About Merlin BioSciences
Merlin Biosciences Limited is a venture capital firm specializing in life sciences sector with a focus on human medicines or medical devices. It prefers to be an active investor and seeks to take a seat on the board of directors of its portfolio companies. Merlin BioSciences changed its name to Excalibur Fund Managers Limited.
Want to inform investors similar to Merlin BioSciences about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Merlin BioSciences Investments
4 Investments
Merlin BioSciences has made 4 investments. Their latest investment was in Neurotech as part of their Series C - II on March 3, 2010.
Merlin BioSciences Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/10/2010 | Series C - II | Neurotech | $15M | No | 3i Group, Abenex, AGF Private Equity, Alpha Engineered Composites, Altamir Amboise SCR, Apax Partners, Atlas Venture, AVIDA Equity Partners, Banexi Ventures, Banque de Vizille, Burrill & Company, Excalibur Fund Managers, Fondinvest Capital, Gimv, Industrie Management Holding, Merlin BioSciences, Nexus Medical Partners, Omega Advisors, Omega Funds, Pound Capital, Private Equity Holding AG, Qualium Investissement, Rothschild Gestion, Sofinnova Partners, Sudinnova, SV Health Investors, Triginta Capital, Triginta Capital GmbH, Versant Ventures, and XAnge | |
5/4/2007 | Series D | |||||
12/14/1998 | Series B | |||||
Series A |
Date | 3/10/2010 | 5/4/2007 | 12/14/1998 | |
|---|---|---|---|---|
Round | Series C - II | Series D | Series B | Series A |
Company | Neurotech | |||
Amount | $15M | |||
New? | No | |||
Co-Investors | 3i Group, Abenex, AGF Private Equity, Alpha Engineered Composites, Altamir Amboise SCR, Apax Partners, Atlas Venture, AVIDA Equity Partners, Banexi Ventures, Banque de Vizille, Burrill & Company, Excalibur Fund Managers, Fondinvest Capital, Gimv, Industrie Management Holding, Merlin BioSciences, Nexus Medical Partners, Omega Advisors, Omega Funds, Pound Capital, Private Equity Holding AG, Qualium Investissement, Rothschild Gestion, Sofinnova Partners, Sudinnova, SV Health Investors, Triginta Capital, Triginta Capital GmbH, Versant Ventures, and XAnge | |||
Sources |
Merlin BioSciences Portfolio Exits
2 Portfolio Exits
Merlin BioSciences has 2 portfolio exits. Their latest portfolio exit was Neurotech on November 12, 2012.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.